Mathew Martin

Dr. Mathew Martin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cell Chemical Biology
Verified
Journal Article
Open access
DWDaniel J. Wood
Daniel J. Wood
SKSvitlana Korolchuk
Svitlana Korolchuk
NTNatalie J. Tatum
Natalie J. Tatum
LWLan-Zhen Wang
Lan-Zhen Wang
JEJane A. Endicott
Jane A. Endicott
MMMathew Martin
Mathew Martin
Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for developing cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target certain cancers in which CCNE1 is amplified. However, current CDK2 inhibitors also inhibit CDK1, generating a toxicity liability. We have used biophysical measurements and X-ray crystallography to investigate the ATP-competitive inhibitor binding properties of cyclin-free and cyclin-bound CDK1 and CDK2. We show that these kinases can readily be distinguished by such inhibitors when cyclin-free, but not when cyclin-bound. The basis for this discrimination is unclear from either inspection or molecular dynamics simulation of ligand-bound CDKs, but is reflected in the contacts made between the kinase N- and C-lobes. We conclude that there is a subtle but profound difference between the conformational energy landscapes of cyclin-free CDK1 and CDK2. The unusual properties of CDK1 might be exploited to differentiate CDK1 from other CDKs in future cancer therapeutic design.

27 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAlice Douangamath
Alice Douangamath
DFDaren Fearon
Daren Fearon
PGPaul Gehrtz
Paul Gehrtz
TKTobias Krojer
Tobias Krojer
PLPetra Lukacik
Petra Lukacik
MWMartin Walsh
Martin Walsh
Summary: COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments was progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease.

27 October 2022 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
PDF file
MMMathew Martin
Mathew Martin
MNMartin E. M. Noble
Martin E. M. Noble
Crystallographic fragment screens provide an efficient and effective way to identify small-molecule ligands of a crystallized protein. Due to their low molecular weight, such hits tend to have low, often unquantifiable, affinity for their target, complicating the twin challenges of validating the hits as authentic solution-phase ligands of the target and identifying the `best' hit(s) for further elaboration. In this article, approaches that address these challenges are assessed. Using retrospective analysis of a recent ATAD2 hit-identification campaign, alongside other examples of successful fragment-screening campaigns, it is suggested that hit validation and prioritization are best achieved by a `triangulation' approach in which the results of multiple available biochemical and biophysical techniques are correlated to develop qualitative structure–activity relationships (SARs). Such qualitative SARs may indeed be the only means by which to navigate a project through the tunnel of uncertainty that prevails before on-scale biophysical, biochemical and/or biological measurements become possible.

15 August 2025 in Structure
Verified
Journal Article
Open access
IHIan Hope
Ian Hope
MMMathew Martin
Mathew Martin
ZJZiwei Jiang
Ziwei Jiang
MWMichael J. Waring
Michael J. Waring
MNMartin E.M. Noble
Martin E.M. Noble
NTNatalie J. Tatum
Natalie J. Tatum
Sites of protein-protein interaction (PPI) are potentially more selective binding sites for therapeutics than protein substrate-binding sites. PPIs include distinct regions frequently called "hotspots," sites of key amino acid interactions. Prospective identification of these hotspots through X-ray crystallographic screening could assist in the identification of separation of function mutants for experimental validation, enhance confidence in AI-generated multiprotein complex predictions, and accelerate development of selective chemical probes. To explore these applications, we utilize the FragLite library to examine the binding surfaces of CDK2-cyclin A. The many protein- and peptide-CDK2-cyclin A complexes that have been structurally characterized make this complex an appropriate test case. We show that FragLites comprehensively map both known sites of protein-protein interaction on CDK2-cyclin A and identify a possible uncharacterized site, providing a structural method toward directing mechanistic studies and starting points for chemical probe design.

18 January 2025 in Current Opinion in Structural Biology
Verified
Journal Article
Open access
JWJessica Watt
Jessica Watt
MMMathew Martin
Mathew Martin
JEJane A. Endicott
Jane A. Endicott
MNMartin.E.M. Noble
Martin.E.M. Noble
Macromolecular X-ray crystallography allows detection and characterisation of the binding of small, low-affinity chemical fragments. Here we review the utility of fragment screening for drug discovery, its potential for use in discovery science, as well as some of the distinct types of fragments that have been compiled into libraries.

Verified
Journal Article
Open access
PDF file
JTJulie Tucker
Julie Tucker
MMMathew Martin
Mathew Martin
This special issue on Advances in Kinase Drug Discovery provides a selection of research articles and topical reviews covering all aspects of drug discovery targeting the phosphotransferase enzyme family